Use of Intravenous Immunoglobulin Projected to Continue Growing Over Next Decade

The use of intravenous immunoglobulin (IVIG) has grown exponentially in recent years, with IVIG increasingly being tapped for the treatment of several diseases. The rise in IVIG use across autoimmune disease states has helped to lower the burden and prevalence of primary immunodeficiency (PID) diseases, which has resulted in greater growth opportunities in the IVIG market, which could reach $20.5 billion over the next decade, according to a report by Transparency Market Research.

The report notes that expanding the target IVIG patient population has prompted research and development efforts specifically in innovative purification and production methods with IV modes of delivery achieving greater clinical acceptance for some medications, especially for use in children. Current development efforts in IVIG are focused on new routes of administration for immunoglobulin that can overcome the limitations of intramuscular administration, according to the report.

Multiple clinical trials have sought to evaluate the use of IVIG in treating the SARS-CoV-2 virus. Additional studies are ongoing to improve the safety and tolerability of IVIG for symptomatic secondary immunodeficiency, autoinflammatory diseases, and C1 inhibitor deficiency, which could reveal promising new treatment paths, according to the report. The analysis further noted that the outlook for IVIG market is enhanced by randomized trials evaluating the efficacy of immunoglobulin replacement therapy in treating primary antibody deficiency (PAD).

The analysis found that greater use of IVIG is being spurred by significant demand for these products in the treatment of patients with antibody deficiencies, specifically for PAD. Notably, a growing need for treatments for hypogammaglobinemia have produced significant revenue opportunities for manufacturers of IVIG products, according to the report.

As acceptance of IVIG replacement therapy has increased for an array of antibody deficiency diseases, so too has the need for new IVIG preparations. These opportunities have expanded with the high incidence rate for PID and its recurrent infections, illustrating the need for effective treatments for this indication. Use of IVIG has also seen an uptick in hospital settings, which is the preferential treatment site for immunodeficiency disorders, according to Transparency Market Research. The authors wrote that higher footfalls in hospitals versus standalone clinics helped this segment account for the leading share of the global IVIG market last year.

Key drivers of research into IVIG include the prevalence of PAD syndromes and the high burden on the patient population. The report notes that advancements in the routes of administration and growth of clinical research into the safety and efficacy of immunoglobin products have expanded the opportunities in this area.

Reference

Intravenous Immunoglobulin Market to Advance at CAGR of 7.3% During 2022–2031: TMR Study. Transparency Market Research. News release. Accessed June 15, 2022. https://www.globenewswire.com/news-release/2022/05/30/2452494/0/en/Intravenous-Immunoglobulin-Market-to-Advance-at-CAGR-of-7-3-During-2022-2031-TMR-Study.html